The Discovery of Vorapaxar (SCH 530348), a Thrombin Receptor (Protease Activated Receptor-1) Antagonist with Potent Antiplatelet Effects - Accounts in Drug Discovery Case Studies in Medicinal Chemistry - page 48

10. J. L. Vacek, Postgrad. Med., 2002, 112, 71.
11. P. Libby, Circulation, 2001, 104, 365.
12. Z. Bereczky, E. Katona and L. Muszbek, Pathophysiol. Haemost. Thromb.,
2003, 33, 430.
13. M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L.
Wallentin, R. M. Califf, R. A. Harrington and R. P. Giugliano, J. Am.
Coll. Cardiol., 2009, 54, 969.
14. G. S. Bisacchi, in Burger's Medicinal Chemistry and Drug Discovery, 6th
edn, ed. D. J. Abraham, Wiley, Hoboken, NJ, 2003, vol. 3, p. 283.
15. K. K. Wu and N. Matijevic-Aleksic, Crit. Rev. Clin. Lab. Sci., 2005, 42,
249.
16. S. Moll and I. I. White, in Principles of Molecular Medicine, 2nd edn,
ed. M. S. Runge and C. Patterson, Humana Press, Totowa NJ, 2006,
p. 871.
17. D. Feinbloom and K. A. Bauer, Arterioscl. Thromb. Vasc. Biol., 2005, 25,
2043.
18. J. Harenberg, Semin. Thromb. Hemost., 2008, 34, 779.
19. J. A. Cairns, P. Theroux, H. D. Lewis Jr, M. Ezekowitz and T. W. Meade,
Chest, 2001, 119(1S), 228S.
20. J. I. Weitz and L. A. Linkins, Expert Opin. Invest. Drugs, 2007, 16, 271.
21. S. Goto, Curr. Vasc. Pharmacol., 2004, 2, 23.
22. H. R. Lijnen and D. Collen, Thromb. Haemost., 1995, 74, 387.
23. H. J. Weiss, New Engl. J. Med., 1975, 293, 531.
24. H. J. Weiss, New Engl. J. Med., 1975, 293, 580.
25. Z. M. Ruggeri, J. A. Dent and E. Saldivar, Blood, 1999, 94, 172.
26. R. K. Andrews and M. C. Berndt, Histol. Histopathol., 1998, 13, 837.
27. H. Shankar, B. Kahner and S. P. Kunapuli, Curr. Drug Targets, 2006, 7,
1253.
28. C. S. Abrams and L. F. Brass, in Hemostasis and Thrombosis, 5th edn, ed.
R. W. Colman, V. J. Marder, A. W. Clowes, J. N. George and S. Z.
Goldhaber, Lippincott Williams & Wilkins, Philadelphia, 2006, p. 617.
29. S. R. Coughlin, Thromb. Haemost., 1999, 82, 353.
30. S. Offermanns, Circ. Res., 2006, 99, 1293.
31. H. Mohri and T. Ohkubo, Peptides, 1993, 14, 353.
32. H. Ni, C. V. Denis, S. Subbarao, J. L. Degen, T. N. Sato, R. O. Hynes and
D. D. Wagner, J. Clin. Invest., 2000, 106, 385.
33. Antithrombotic Trialists' Collaboration, Br. Med. J., 2002, 324, 71.
34. H. Tran and S. S. Anand, J. Am. Med. Assoc., 2004, 292, 1867.
35. S. R. Coughlin, Proc. Natl. Acad. Sc. U. S. A., 1999, 96, 11023.
36. S. R. Coughlin, J. Thromb. Haemost., 2005, 3, 1800.
37. P. J. O'Brien, M. Molino, M. Kahn and L. Brass, Oncogene, 2001, 20,
1570.
38. B. Al-Ani, M. Saifeddine and M. D. Hollenberg, Can. J. Physiol. Phar-
macol., 1995, 73, 1203.
39. H. Ishihara, A. J. Connolly, D. Zeng, M. L. Kahn, Y. W. Zheng, C.
Timmons, T. Tram and S. R. Coughlin, Nature, 1997, 386, 502.